Overview

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

Status:
Completed
Trial end date:
2020-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is: - to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke - to evaluate safety of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke
Phase:
Phase 3
Details
Lead Sponsor:
Materia Medica Holding